A First-in-Human Trial to Evaluate the Safety and Immunogenicity of a G Protein-Based Recombinant Respiratory Syncytial Virus Vaccine in Healthy Adults 18–45 Years of Age

Background: With the enormous morbidity and mortality caused by respiratory syncytial virus (RSV) infections among infants and the elderly, vaccines against RSV infections are in large market demand. Methods: We conducted a first-in-human (FIH), randomized, double-blind, placebo-controlled dose esca...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Xin, Zhao, Gan, Dong, Aihua, He, Zhonghuai, Wang, Jiarong, Jiang, Brian, Wang, Bo, Wang, Miaomiao, Huai, Xuefen, Zhang, Shijie, Feng, Shuangshuang, Qin, Hong, Wang, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221330/
https://www.ncbi.nlm.nih.gov/pubmed/37243103
http://dx.doi.org/10.3390/vaccines11050999

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221330/
https://www.ncbi.nlm.nih.gov/pubmed/37243103
http://dx.doi.org/10.3390/vaccines11050999

Ejemplares similares